Management of schizophrenia: Defining the role of long-acting injectable risperidone

Disease Management and Health Outcomes

Volumn 14, Issue 2, 2006, Pages 107-125

  Curran, Monique P ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIPOTIAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AKATHISIA; ANXIETY DISORDER; AREA UNDER THE CURVE; CATATONIA; CLINICAL TRIAL; CONSTIPATION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TOLERABILITY; DYSPEPSIA; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GALACTORRHEA; GYNECOMASTIA; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; INJECTION; INJECTION SITE; INSOMNIA; MAJOR DEPRESSION; MENSTRUATION DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSESSIVE COMPULSIVE DISORDER; PARKINSONISM; PROLACTIN BLOOD LEVEL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TARDIVE DYSKINESIA; WEIGHT GAIN; XEROSTOMIA;

EID: 33646420877     PISSN: 11738790     EISSN: 11738790     Source Type: Journal    
DOI: 10.2165/00115677-200614020-00006     Document Type: Review

References (95)

1. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6 (3): 132-91
2. National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance 2002 Jun; 43: 1-20
3. Mortimer AM. Novel antipsychotics in schizophrenia. Expert Opin Investig Drugs 2004 Apr; 13 (4): 315-29
4. American Psychiatric Association. Practice guideline for the treatment ofpatients with schizophrenia, second edition [online]. Available from http://www.psych.org/psych_pract/treatg/pg/Practice%20Guidelines8904/ Schizophrenia_2e.pdf [Accessed 2006 Mar 22]
5. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003 Apr; 54 (4): 508-16
6. Keith SJ, Pani L, Nick B, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004 Sep; 55 (9): 997-1005
7. Valenstein M, Copeland LA, Owen R, et al. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001 Jul; 62 (7): 545-51
8. Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001 Oct; 179: 290-9
9. Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull 1984; 10 (2): 300-12
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Arlington (VA): American Psychiatric Association, 2000
11. Beiser M, Erickson D, Fleming JA, et al. Establishing the onset of psychotic illness. Am J Psychiatry 1993 Sep; 150 (9): 1349-54
12. Ḧafner H, Maurer K, Löffler W, et al. Modeling the early course of schizophrenia. Schizophr Bull 2003; 29 (2): 325-40
13. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999 Mar; 56 (3): 241-7
14. McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004 Apr 28; 2: 13
15. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med 2005 May; 2 (5): e141
16. Torrey EF. Prevalence studies in schizophrenia. Br J Psychiatry 1987 May; 150: 598-608
17. World Health Organization. World Health Report 2001 - mental health: new understanding, new hope [online]. Available from URL: http://www.who.int/whr/ 2001/en/whr01_en.pdf [Accessed 2005 Apr 5]
18. Kestenbaum CJ. Children at risk for schizophrenia. Am J Psychother 1980 Apr; 34 (2): 164-77
19. Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004; 18 Suppl. 2: 5-17
20. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004; 18 (13): 877-93
21. Rössler W, Salize HJ, van Os J, et al. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005 Aug; 15 (4): 399-409
22. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004; 30 (2): 279-93
23. Knapp M, Chisholm D, Leese M, et al. Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. Acta Psychiatr Scand 2002 Jan; 105: 42-54
24. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005 Sep; 66 (9): 1122-9
25. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 1997; 58 Suppl. 10: 50-4
26. Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia - 1991. Soc Psychiatry Psychiatr Epidemiol 1995 Aug; 30 (5): 196-205
27. Surles RC. Atypical antipsychotics: considerations for Medicaid coverage. Am J Manag Care 2005 Sep; 11 (8 Suppl.): S248-53
28. Hamann J, Leucht S, Kissling W. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry 2003 Jan; 36 (1): 18-26
29. Lasser RA, Bossie CA, Gharabawi GM, et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004 Jun; 19 (4): 219-25
30. Farmer D, Claerhout B, Mehnert A, et al. e-STAR: the electronic schizophrenia treatment adherence registry. An electronic registry to evaluate outcomes data in patients. Value Health 2004; 7 (6 Suppl. 1): 778
31. Mauskopf J, Muroff M, Gibson PJ, et al. Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia. Schizophr Bull 2002; 28 (4): 619-35
32. Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 2005; 23 Suppl. 1: 3-16
33. National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care [online]. Available from URL: http://www.nice.org.uk/page.aspx?o= 42424 [Accessed 2006 Mar 22]
34. McEvoy JP, Scheifler PL, Frances A, et al. Treatment of schizophrenia 1999: the expert consensus guideline series. J Clin Psychiatry 1999; 60 Suppl. 11: 3-80
35. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004; 30 (2): 193-217
36. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004 Mar; 14 (2): 87-92
37. Donohoe G, Owens N, O'Donnell C, et al. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 2001 Aug; 16 (5): 293-8
38. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353 (12): 1209-23
39. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004 Aug; 55 (8): 886-91
40. O'Donnell C, Donohoe G, Sharkey L, et al. Compliance therapy: a randomised controlled trial in schizophrenia. BMJ 2003 Oct 11; 327 (7419): 834
41. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs RD 2005; 6 (3): 129-37
42. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003; 64 Suppl. 16: 34-40
43. Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003; 63 (5): 493-512
44. Schooler NR. Relapse and rehospitalization: comparing oral and depot. J Clin Psychiatry 2003; 64 Suppl. 16: 14-7
45. Barnes TR, Curson DA. Long-term depot antipsychotics: a risk-benefit assessment. Drug Saf 1994 Jun; 10 (6): 464-79
46. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001 Oct; 179: 300-7
47. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003; 64 Suppl. 16: 18-23
48. Remington G, Chong SA. Conventional versus novel antipsychotics: changing concepts and clinical implications. J Psychiatry Neurosci 1999 Nov; 24 (5): 431-41
49. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005 Jun 21; 172 (13): 1703-11
50. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001 Apr; 158 (4): 518-26
51. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003 May 10; 361 (9369): 1581-9
52. Miller AL, Chiles JA, Chiles JK, et al. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999 Oct; 60 (10): 649-57
53. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999 Nov; 156 (11): 1686-96
54. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 Suppl. 18: 36-46
55. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 Suppl. 18: 27-35
56. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64 (20): 2291-314
57. Janssen Pharmaceutical Ltd. Risperdal® Consta® - risperidone long-acting injection: US prescribing information. Titusville (NJ): Janssen Pharmaceutical Ltd, 2005
58. Janssen Pharmaceutical Products. Risperdal® (risperidone tablets/oral solution): US prescribing information. Titusville (NJ): Janssen Pharmaceutical Products, 2005
59. Otsuka America Pharmaceutical, Inc. Abilify® (aripiprazole) tablets: US prescribing information. Rockville (MD): Otsuka America Pharmaceutical, Inc., 2005 Dec
60. Eli Lilly and Company. Zyprexa® (olanzapine): US prescribing information. Indianapolis (IN): Eli Lilly and Company, 2005
61. Eli Lilly Nederland B.V. Zyprexa®: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/ zyprexa/zyprexa.htm [Accessed 2006 Mar 22]
62. AstraZeneca Pharmaceuticals LP. Seroquel® (quetiapine fumarate) tablets: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP, 2005
63. Pfizer, Inc. Geodon® (ziprazone): US prescribing information. New York (NY): Pfizer, Inc., 2005 May
64. McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004; 18 (13): 933-56
65. Novartis Pharmaceuticals Corporation. Clozaril® (clozapine) tablets: US prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2005 May
66. Smith S, Wheeler MJ, Murray R, et al. The effects of antipsychotic- induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002 Apr; 22 (2): 109-14
67. Huxley NA, Rendall M, Sederer L. Psychosocial treatments in schizophrenia: a review of the past 20 years. J Nerv Ment Dis 2000 Apr; 188 (4): 187-201
68. Royal Australian and New Zealand College of Psychiatrists. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005 Jan-2005 28; 39 (1-2): 1-30
69. Lehman AF, Goldberg R, Dixon LB, et al. Improving employment outcomes for persons with severe mental illnesses. Arch Gen Psychiatry 2002 Feb; 59 (2): 165-72
70. Swainston Harrison T, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 2004; 18 (2): 113-32
71. Chue P. Risperidone long-acting injection. Expert Rev Neurotherapeutics 2003; 3 (4): 435-46
72. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003 Jun; 160: 1125-32
73. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005 Jan; 15 (1): 111-7
74. Taylor DM, Young CL, Mace S, et al. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004 Aug; 65 (8): 1076-83
75. Turner M, Eerdekens E, Jacko M, et al. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004 Jul; 19 (4): 241-9
76. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003 Oct; 64 (10): 1250-7
77. Möller HJ, Llorca PM, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005 May; 20 (3): 121-30
78. Marder SR, Conley R, Ereshefsky L, et al. Clinical guidelines: dosing and switching strategies for long-acting risperidone. J Clin Psychiatry 2003; 64 Suppl. 16: 41-6
79. Lauriello J, McEvoy JP, Rodriguez S, et al. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res 2005 Jan 1; 72 (2-3): 249-58
80. Parellada E, Andrezina R, Milanova V, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol (Oxf) 2005 Sep; 19 (5): 5-14
81. Gastpar M, Masiak M, Latif MA, et al. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol 2005 Sep; 19 (5 Suppl.): 32-8
82. Kissling S, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone - analysis of long-term efficacy. J Psychopharmacol (Oxf) 2005 Sep; 19 (5): 15-21
83. Chue P, Llorca PM, Duchesne I, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 2005; 5 (2): 266-74
84. Leal A, Rosillon D, Mehnert A, et al. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf 2004 Nov; 13 (11): 811-6
85. Lindenmayer JP, Jarboe K, Bossie CA, et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 2005 Jul; 20 (4): 213-21
86. Bloch Y, Mendlovic S, Strupinsky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001 Nov; 62 (11): 855-9
87. Hay J. Complications at site of injection of depot neuroleptics. BMJ 1995 Aug 12; 311 (7002): 421
88. McHorney CA, Ware Jr JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993 Mar; 31 (3): 247-63
89. Nasrallah HA, Duchesne I, Mehnert A, et al. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 2004 Apr; 65 (4): 531-6
90. Fleischhacker WW, Rabinowitz J, Kemmler G, et al. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry 2005 Aug; 187: 131-6
91. De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005; 23 Suppl. 1: 35-47
92. Llorca PM, Miadi-Fargier H, Lançon C, et al. Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation [in French]. Encephale 2005 Mar-Apr 30; 31 (2): 235-46
93. Chue PS, Heeg BMS, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005; 23 Suppl. 1: 62-74
94. Edwards NC, Rupnow MFT, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 2005; 23 (3): 299-314
95. Laux G, Heeg BMS, Van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005; 23 Suppl. 1: 49-61